Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Condition:   Gastric, or Gastroesophageal Junction Adenocarcinoma Interventions:   Drug: Tislelizumab (BGB-A317) combined with oxaliplatin and capecitabine or Tislelizumab (BGB-A317) combined with Cisplatin and 5-FU;   Drug: Placebo combined with oxaliplatin and capecitabine or Placebo combined with Cisplatin and 5-FU Sponsor:   BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials